JP2002527522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002527522A5 JP2002527522A5 JP2000577180A JP2000577180A JP2002527522A5 JP 2002527522 A5 JP2002527522 A5 JP 2002527522A5 JP 2000577180 A JP2000577180 A JP 2000577180A JP 2000577180 A JP2000577180 A JP 2000577180A JP 2002527522 A5 JP2002527522 A5 JP 2002527522A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- embedded image
- effective amount
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 31
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 125000003710 aryl alkyl group Chemical group 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 10
- 0 *[C@]1[C@]([n]2nc(C(N)=O)nc2)O[C@@](CO)C1 Chemical compound *[C@]1[C@]([n]2nc(C(N)=O)nc2)O[C@@](CO)C1 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 9
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 7
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 125000001475 halogen functional group Chemical group 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 description 4
- 108010079944 Interferon-alpha2b Proteins 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- NJQHZENQKNIRSY-UHFFFAOYSA-N CCc1c[nH]cn1 Chemical compound CCc1c[nH]cn1 NJQHZENQKNIRSY-UHFFFAOYSA-N 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- XQYRHNCOXPZOBR-UHFFFAOYSA-N CCC(C)C(C(C)=O)N Chemical compound CCC(C)C(C(C)=O)N XQYRHNCOXPZOBR-UHFFFAOYSA-N 0.000 description 2
- HXDOZKJGKXYMEW-UHFFFAOYSA-N CCc(cc1)ccc1O Chemical compound CCc(cc1)ccc1O HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 2
- GOVXKUCVZUROAN-UHFFFAOYSA-N CCc1c[nH]c2ccccc12 Chemical compound CCc1c[nH]c2ccccc12 GOVXKUCVZUROAN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical group [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- -1 alkenoyl Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- GYUQZZUOSXLVGY-JHOLWCCGSA-N C/C(/C(C1)NC[C@@H]1O)=[O]\CC([C@@H](C1)NC[C@@H]1O)=O Chemical compound C/C(/C(C1)NC[C@@H]1O)=[O]\CC([C@@H](C1)NC[C@@H]1O)=O GYUQZZUOSXLVGY-JHOLWCCGSA-N 0.000 description 1
- FADKJNSSIWTVAI-UHFFFAOYSA-N CC(C(CCCCN)N)=O Chemical compound CC(C(CCCCN)N)=O FADKJNSSIWTVAI-UHFFFAOYSA-N 0.000 description 1
- AGTDSFXRPBMMGQ-UHFFFAOYSA-N CC(C1)NCC1O Chemical compound CC(C1)NCC1O AGTDSFXRPBMMGQ-UHFFFAOYSA-N 0.000 description 1
- FYCFJMPASVKULQ-ZCFIWIBFSA-N CC([C@@H]1NCCC1)=O Chemical compound CC([C@@H]1NCCC1)=O FYCFJMPASVKULQ-ZCFIWIBFSA-N 0.000 description 1
- FYCFJMPASVKULQ-LURJTMIESA-N CC([C@H]1NCCC1)=O Chemical compound CC([C@H]1NCCC1)=O FYCFJMPASVKULQ-LURJTMIESA-N 0.000 description 1
- XQYRHNCOXPZOBR-DSEUIKHZSA-N CC[C@H](C)C(C(C)=O)N Chemical compound CC[C@H](C)C(C(C)=O)N XQYRHNCOXPZOBR-DSEUIKHZSA-N 0.000 description 1
- XQYRHNCOXPZOBR-FSPLSTOPSA-N CC[C@H](C)[C@@H](C(C)=O)N Chemical compound CC[C@H](C)[C@@H](C(C)=O)N XQYRHNCOXPZOBR-FSPLSTOPSA-N 0.000 description 1
- GVZLPXMWICXSCL-DUXGTMBRSA-N C[C@@H](C(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1nc(C(N)=O)nc1)=O)N Chemical compound C[C@@H](C(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1nc(C(N)=O)nc1)=O)N GVZLPXMWICXSCL-DUXGTMBRSA-N 0.000 description 1
- IMBGTZUFPDICOQ-ZCFIWIBFSA-N C[NH+]([C@H](CCCCN)N)[O-] Chemical compound C[NH+]([C@H](CCCCN)N)[O-] IMBGTZUFPDICOQ-ZCFIWIBFSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N NC(c1n[n]([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)cn1)=O Chemical compound NC(c1n[n]([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)cn1)=O IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17405998A | 1998-10-16 | 1998-10-16 | |
| US09/174,059 | 1998-10-16 | ||
| US09/348,534 | 1999-07-07 | ||
| US09/348,534 US6277830B1 (en) | 1998-10-16 | 1999-07-07 | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| PCT/US1999/021448 WO2000023454A1 (en) | 1998-10-16 | 1999-10-14 | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002527522A JP2002527522A (ja) | 2002-08-27 |
| JP2002527522A5 true JP2002527522A5 (https=) | 2006-12-14 |
Family
ID=26869824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000577180A Pending JP2002527522A (ja) | 1998-10-16 | 1999-10-14 | 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121369B1 (https=) |
| JP (1) | JP2002527522A (https=) |
| CN (1) | CN1330658A (https=) |
| AT (1) | ATE284408T1 (https=) |
| AU (1) | AU762395B2 (https=) |
| BR (1) | BR9915546A (https=) |
| CA (1) | CA2346447C (https=) |
| CZ (1) | CZ20011130A3 (https=) |
| DE (1) | DE69922529T2 (https=) |
| ES (1) | ES2229820T3 (https=) |
| HU (1) | HUP0200447A2 (https=) |
| ID (1) | ID29187A (https=) |
| IL (1) | IL142423A0 (https=) |
| NO (1) | NO20011789L (https=) |
| NZ (1) | NZ510811A (https=) |
| PL (1) | PL347268A1 (https=) |
| RU (1) | RU2001113268A (https=) |
| SK (1) | SK4742001A3 (https=) |
| TR (1) | TR200101085T2 (https=) |
| WO (1) | WO2000023454A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924270B2 (en) | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| WO2004084796A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset Ltd. | Compounds for the treatment of flaviviridae infections |
| JP2007501806A (ja) * | 2003-08-13 | 2007-02-01 | ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー | ウィルス感染を治療する方法 |
| WO2005049065A2 (en) * | 2003-11-19 | 2005-06-02 | Rigel Pharmaceuticals, Inc. | Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
| JP2008540425A (ja) | 2005-05-02 | 2008-11-20 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用 |
| WO2009028575A1 (ja) | 2007-08-27 | 2009-03-05 | National University Corporation Nagoya University | 血液凝固第vii因子プロモーターの活性化剤及びその利用 |
| WO2009028573A1 (ja) | 2007-08-27 | 2009-03-05 | National University Corporation Nagoya University | 血液凝固障害におけるリバビリンの利用 |
| WO2011151667A1 (en) | 2010-06-02 | 2011-12-08 | Adbula Kurkayev | Antiviral compositions |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| CA3033867A1 (en) | 2016-08-17 | 2018-02-22 | Solstice Biologics, Ltd. | Polynucleotide constructs |
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| CN107513055B (zh) * | 2017-08-11 | 2018-06-22 | 广东昊邦医药健康有限责任公司 | 一种利巴韦林衍生化合物及其药物组合物 |
| CN117355311A (zh) | 2022-05-05 | 2024-01-05 | 阿卜杜拉·库尔卡耶夫 | 用于恢复生物体生理过程和细胞的药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1482736A (en) * | 1974-03-18 | 1977-08-10 | Icn Pharmaceuticals | 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives |
| US4544741A (en) * | 1982-03-29 | 1985-10-01 | Robins Roland K | Azole dinucleotide compounds and methods for their production |
| US4925930A (en) * | 1988-11-02 | 1990-05-15 | Nucleic Acid Research Institute | Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates |
| GB9307043D0 (en) * | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| WO1998021223A1 (en) * | 1996-11-12 | 1998-05-22 | Medivir Ab | Nucleosides |
-
1999
- 1999-10-14 TR TR2001/01085T patent/TR200101085T2/xx unknown
- 1999-10-14 BR BR9915546-0A patent/BR9915546A/pt not_active IP Right Cessation
- 1999-10-14 NZ NZ510811A patent/NZ510811A/xx unknown
- 1999-10-14 RU RU2001113268/04A patent/RU2001113268A/ru not_active Application Discontinuation
- 1999-10-14 ES ES99970662T patent/ES2229820T3/es not_active Expired - Lifetime
- 1999-10-14 EP EP99970662A patent/EP1121369B1/en not_active Expired - Lifetime
- 1999-10-14 CZ CZ20011130A patent/CZ20011130A3/cs unknown
- 1999-10-14 HU HU0200447A patent/HUP0200447A2/hu unknown
- 1999-10-14 AT AT99970662T patent/ATE284408T1/de not_active IP Right Cessation
- 1999-10-14 DE DE69922529T patent/DE69922529T2/de not_active Expired - Fee Related
- 1999-10-14 ID IDW20010844A patent/ID29187A/id unknown
- 1999-10-14 AU AU11975/00A patent/AU762395B2/en not_active Ceased
- 1999-10-14 JP JP2000577180A patent/JP2002527522A/ja active Pending
- 1999-10-14 WO PCT/US1999/021448 patent/WO2000023454A1/en not_active Ceased
- 1999-10-14 IL IL14242399A patent/IL142423A0/xx unknown
- 1999-10-14 CN CN99814344A patent/CN1330658A/zh active Pending
- 1999-10-14 SK SK474-2001A patent/SK4742001A3/sk unknown
- 1999-10-14 CA CA002346447A patent/CA2346447C/en not_active Expired - Fee Related
- 1999-10-14 PL PL99347268A patent/PL347268A1/xx not_active Application Discontinuation
-
2001
- 2001-04-09 NO NO20011789A patent/NO20011789L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002527522A5 (https=) | ||
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP2004509061A5 (https=) | ||
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| RU2001113268A (ru) | Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с | |
| JP2002543144A5 (https=) | ||
| US20110033422A1 (en) | Treatments for flaviviridae virus infection | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| RU2011133741A (ru) | Модифицированные 2'- и 3'-нуклеозиды и их применение для получения лекарственного средства для лечения инфекций flaviviridae | |
| JP2007532479A5 (https=) | ||
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| SA99200208B1 (ar) | إستخدام PEG-IFN- وريبافيرين ribavirin لمعالجة الإلتهاب الكبدي C المزمن | |
| CA2245938A1 (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| PL366159A1 (en) | Methods and compositions for treating hepatitis c virus | |
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| JP2004503564A5 (https=) | ||
| DK1090645T3 (da) | Oral tilförsel af kemisk modificerede proteiner | |
| PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
| JP3838034B2 (ja) | Ｃ型肝炎治療効果の改善剤及びその応用 | |
| JPWO1999018993A1 (ja) | Ｃ型肝炎治療効果の改善剤及びその応用 | |
| JP2025505673A5 (https=) | ||
| US20030031647A1 (en) | IFN-alpha and amantadine for treating hepatitis C | |
| RU2004116067A (ru) | Фармацевтические композиции, содержащие макролиды | |
| RU2009128978A (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций | |
| KR960703924A (ko) | 항바이러스제로서 신규한 벤조티오펜 유사체(Novel Benzothiophene Analogs as Antiviral Agents) |